ClinicalTrials.gg
CompletedNCT05432830Updated Oct 2, 2026Results posted

Sex Differences in E-cig Perception: Study 1

An interventional study of E-liquid Flavor 1 and E-liquid Flavor 2 in Nicotine Addiction, E-Cig Use and Cigarette Smoking, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 21 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Yale University · Not applicable, Interventional, and Other

How we know

Updated Oct 2, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
21 Years to 44 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 58 studies in Tobacco Use Disorder by Yale University — 5 open to participants now, 5 under way, none of them phase 3. Tobacco Use Disorder · Yale University.

Enrollment
17th of 56
66 · median 41
Started
2024
with 2 others
No phase
20 of 58
3 open now
Registered
51st of 58
by date

Among the 58 studies in Tobacco Use Disorder by Yale University, this one is the 17th largest by enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2024, is one of 20 with no phase, and was the 51st registered.

Tobacco Use Disorder

1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.

Browse Tobacco Use Disorder studies →

Open to participants now

5 of the 58 studies in Tobacco Use Disorder by Yale University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.

This study: 21 Years to 44 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Tobacco Use Disorder by Yale University, or all of them as a file.
02

Study summary

The primary objective is to examine the influence of sex on sensory effects, appeal, and reinforcing value of nicotine containing e-cigs in popular flavor components; sweet and cooling.

Read the detailed description

This study looks at the effect of sex on the sensory effects of flavor components in e-cigarettes. Regular combustible tobacco users will sample 3 different flavored e-cigarettes containing nicotine in a human lab paradigm.

03

Conditions studied

  • Nicotine Addiction
  • E-Cig Use
  • Cigarette Smoking
  • Sex Differences
04

Who can participate

Ages eligible
21 Years to 44 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 21-44 years old
  • Able to read/write
  • Current cigarette smoking
  • Recent E-cig Exposure (>/= 10 uses in past 6 mo.)
  • Urine cot >200ng/ml
  • Willing to abstain from nicotine/tobacco 6-8hrs prior to lab session
  • Not looking to quit

Exclusion criteria

Exclusion Criteria:

  • Untreated chronic medical conditions
  • Non-stable Rx medication
  • Illicit drug use
  • Pregnant, trying to become pregnant, breastfeeding
  • Not fully vaccinated for Coronavirus (e.g. COVID-19)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Experimental E-Liquid Order "A"

    All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).

    Other: E-liquid Flavor 1 · Other: E-liquid Flavor 2 · Other: E-liquid Flavor 3

  • Experimental
    Experimental E-Liquid Order "B"

    All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).

    Other: E-liquid Flavor 1 · Other: E-liquid Flavor 2 · Other: E-liquid Flavor 3

  • Experimental
    Experimental E-Liquid Order "C"

    All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).

    Other: E-liquid Flavor 1 · Other: E-liquid Flavor 2 · Other: E-liquid Flavor 3

Interventions

  • OtherE-liquid Flavor 1

    E-liquid containing 36mg/ml pronated nicotine will be administered with sweet e-cigarette flavor.

  • OtherE-liquid Flavor 2

    E-liquid containing 36mg/ml pronated nicotine will be administered with cooling e-cigarette flavor.

  • OtherE-liquid Flavor 3

    E-liquid containing 36mg/ml pronated nicotine will be administered with unflavored e-cigarette flavor.

06

What researchers measure

Primary outcomes

  1. Appeal

    Change in appeal at each flavor as measured by the computerized Labeled Hedonic Scale (LHS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Labeled Hedonic Scale (LHS) is a bipolar category ratio scale that ranges from -100 (most disliked) to 100 (most liked), with 'neither liked nor disliked' as midpoint.

    Time frame: immediately after intervention (up to 15 minutes)

  2. Sensory Effects Assessed Using the Computerized Generalized Labeled Magnitude Scale (gLMS)

    Change in sweetness at each flavor as measured by the computerized Generalized Labeled Magnitude Scale (gLMS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Generalized Labeled Magnitude Scales (gLMS) are category ratio scales with seven semantic labels: "no sensation", "barely detectable", "weak", "moderate", "strong", "very strong", and "strongest imaginable", positioned quasi-logarithmically as per empirically determined semantic magnitudes on a 0-100 scale (strongest imaginable at the 100 end).

    Time frame: immediately after intervention (up to 15 minutes)

  3. Reinforcing Efficacy of Multiple Choice Procedure

    Change in reinforcing value at each flavor via the Multiple Choice Procedure. Participants will use the Multiple Choice Procedure to self-report their responses using a computer mouse to indicate where across a series of options their answer falls. Following each puffing bout, participants will be asked to make discrete hypothetical choices between 10-puffs of the e-cig they had just used or a series of 10 monetary values ranging from $0.01 to $5.12. The minimum monetary value at which money is chosen over the e-cig puffs is a contingency-based estimate of e-cig value.

    Time frame: immediately after intervention (up to 15 minutes)

07

Results

Posted Oct 2, 2026

Participant flow

Participant flow — Overall Study
MilestoneCondition 1: Strawberry, Then Menthol, Then UnflavoredCondition 2: Strawberry, Unflavored, MentholCondition 3: Menthol, Strawberry, UnflavoredCondition 4: Menthol, Unflavored, StrawberryCondition 5: Unflavored, Strawberry, MentholCondition 6: Unflavored, Menthol, Strawberry
Started101111101113
Completed lab 110101110912
Completed lab 210101110912
Completed lab 310101110912
Completed10101010912
Not completed011021
Withdrew: Lost to follow-up010001
Withdrew: Withdrawal by subject001020

Outcome measures

PrimaryAppeal

Change in appeal at each flavor as measured by the computerized Labeled Hedonic Scale (LHS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Labeled Hedonic Scale (LHS) is a bipolar category ratio scale that ranges from -100 (most disliked) to 100 (most liked), with 'neither liked nor disliked' as midpoint.

Time frame:
immediately after intervention (up to 15 minutes)
Reported as:
Mean · units on a scale
Appeal
units on a scaleMales - Strawberry FlavorMales - Menthol FlavorMales - UnflavoredFemales - Strawberry FlavorFemales - Menthol FlavorFemales - Unflavored
Appeal18.20 ± 5.2714.93 ± 7.04-5.98 ± 7.3013.99 ± 7.527.88 ± 7.76-5.12 ± 6.25
Statistical analysis
  • Males - Strawberry Flavor vs Males - Menthol Flavor vs Males - Unflavored vs Females - Strawberry Flavor vs Females - Menthol Flavor vs Females - Unflavored · Mixed Models Analysis · p = 0.79 (report of the sex x flavor interaction)
PrimarySensory Effects Assessed Using the Computerized Generalized Labeled Magnitude Scale (gLMS)

Change in sweetness at each flavor as measured by the computerized Generalized Labeled Magnitude Scale (gLMS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Generalized Labeled Magnitude Scales (gLMS) are category ratio scales with seven semantic labels: "no sensation", "barely detectable", "weak", "moderate", "strong", "very strong", and "strongest imaginable", positioned quasi-logarithmically as per empirically determined semantic magnitudes on a 0-100 scale (strongest imaginable at the 100 end).

Time frame:
immediately after intervention (up to 15 minutes)
Reported as:
Mean · sweetness score on the gLMS scale
Sensory Effects Assessed Using the Computerized Generalized Labeled Magnitude Scale (gLMS)
sweetness score on the gLMS scaleMales - Strawberry FlavorMales - Menthol FlavorMales - UnflavoredFemales - Strawberry FlavorFemales - Menthol FlavorFemales - Unflavored
Sensory Effects Assessed Using the Computerized Generalized Labeled Magnitude Scale (gLMS)24.73 ± 3.3917.61 ± 3.0910.84 ± 2.6420.62 ± 3.6611.59 ± 2.397.90 ± 1.98
Statistical analysis
  • Males - Strawberry Flavor vs Males - Menthol Flavor vs Males - Unflavored vs Females - Strawberry Flavor vs Females - Menthol Flavor vs Females - Unflavored · Mixed Models Analysis · p = 0.77 (p value represents the interaction of flavor and sex.)
PrimaryReinforcing Efficacy of Multiple Choice Procedure

Change in reinforcing value at each flavor via the Multiple Choice Procedure. Participants will use the Multiple Choice Procedure to self-report their responses using a computer mouse to indicate where across a series of options their answer falls. Following each puffing bout, participants will be asked to make discrete hypothetical choices between 10-puffs of the e-cig they had just used or a series of 10 monetary values ranging from $0.01 to $5.12. The minimum monetary value at which money is chosen over the e-cig puffs is a contingency-based estimate of e-cig value.

Time frame:
immediately after intervention (up to 15 minutes)
Reported as:
Mean · dollars
Reinforcing Efficacy of Multiple Choice Procedure
dollarsMales - Strawberry FlavorMales - Menthol FlavorMales - UnflavoredFemales - Strawberry FlavorFemales - Menthol FlavorFemales - Unflavored
Reinforcing Efficacy of Multiple Choice Procedure2.59 ± 0.512.82 ± 0.611.98 ± 0.532.85 ± 0.611.99 ± 0.452.38 ± 0.43
Statistical analysis
  • Males - Strawberry Flavor vs Males - Menthol Flavor vs Males - Unflavored vs Females - Strawberry Flavor vs Females - Menthol Flavor vs Females - Unflavored · Mixed Models Analysis · p = 0.19 (p value reflects the sex x flavor interaction)

Adverse events

Collected over Adverse events were collected beginning at Lab 1 through Lab 4, including any Adverse events that occur between visits. This time period varies by participants but is approximately 1 week to 1 month.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Strawberry Flavor0/66 (0%)1/66 (1.5%)2/66 (3%)
Menthol Flavor0/66 (0%)1/66 (1.5%)1/66 (1.5%)
Unflavored0/66 (0%)0/66 (0%)0/66 (0%)
Most frequent serious events
Most frequent serious events
EventStrawberry FlavorMenthol FlavorUnflavored
Kidney Stones with an emergency room visitRenal and urinary disorders1/660/660/66
Anaphylactic Reaction to ShellfishGeneral disorders0/661/660/66
Most frequent other events
Most frequent other events
EventStrawberry FlavorMenthol FlavorUnflavored
High Blood PressureVascular disorders1/660/66—
HeadacheNervous system disorders1/660/66—
Abdominal PainInjury, poisoning and procedural complications1/660/66—
Chest PainInjury, poisoning and procedural complications1/660/66—
Difficulty SleepingInjury, poisoning and procedural complications1/660/66—
NauseaGastrointestinal disorders0/661/66—

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Three Lab Sessions in Which a Single Flavor/Lab Session is Administered
<=18 years0
Between 18 and 65 years66
>=65 years0
Age, Continuous
Age, Continuous(years)Three Lab Sessions in Which a Single Flavor/Lab Session is Administered
Mean34.83 ± 6.89
Sex: Female, Male
Sex: Female, Male(Participants)Three Lab Sessions in Which a Single Flavor/Lab Session is Administered
Female35
Male31
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Three Lab Sessions in Which a Single Flavor/Lab Session is Administered
Hispanic or Latino15
Not Hispanic or Latino51
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Three Lab Sessions in Which a Single Flavor/Lab Session is Administered
American Indian or Alaska Native1
Asian7
Native Hawaiian or Other Pacific Islander0
Black or African American20
White31
More than one race0
Unknown or Not Reported7
Region of Enrollment
Region of Enrollment(participants)Three Lab Sessions in Which a Single Flavor/Lab Session is Administered
United States66
Cigarettes Smoked Per Day
Cigarettes Smoked Per Day(cigarettes per day)Three Lab Sessions in Which a Single Flavor/Lab Session is Administered
Mean6.78 ± 4.39
Intake Carbon Monoxide Level
Intake Carbon Monoxide Level(parts per million)Three Lab Sessions in Which a Single Flavor/Lab Session is Administered
Mean17.76 ± 13.19
08

Study locations

1 site
  • Connecticut Mental Health Center
    New Haven, Connecticut 06519, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Jul 2025, 14 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 257 non-industry interventional studies with no phase under Tobacco Use Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's 14 months is below that.

Counting every sponsor, half of 267 studies reached it within 32 months; a quarter within 16 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2022
First posted
Jun 27, 2022
StartActual
Apr 30, 2024
Primary completionActual
Jul 18, 2025
CompletionActual
Jul 18, 2025
Results first posted
Oct 2, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 2, 2026
Primary outcomes
2 edited, 1 time frame changed
What changed in the outcomes
  • EditedReinforcing Efficacy of Multiple Choice ProcedureTime frame: immediately after intervention, up to 15 minutes → immediately after intervention (up to 15 minutes)
  • ChangedBefore Sensory EffectsNow Sensory Effects Assessed Using the Computerized Generalized Labeled Magnitude Scale (gLMS)Time frame: immediately after intervention, up to 15 minutes → immediately after intervention (up to 15 minutes)
  • Time frameAppealimmediately after intervention, up to 15 minutes → immediately after intervention (up to 15 minutes)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Results posted
    Primary outcomes 2 edited, 1 time frame changed
    What changed in the outcomes
    • EditedReinforcing Efficacy of Multiple Choice ProcedureTime frame: immediately after intervention, up to 15 minutes → immediately after intervention (up to 15 minutes)
    • ChangedBefore Sensory EffectsNow Sensory Effects Assessed Using the Computerized Generalized Labeled Magnitude Scale (gLMS)Time frame: immediately after intervention, up to 15 minutes → immediately after intervention (up to 15 minutes)
    • Time frameAppealimmediately after intervention, up to 15 minutes → immediately after intervention (up to 15 minutes)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05432830
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Jun 27, 2022
Start date
Apr 30, 2024
Primary completion
Jul 18, 2025
Completion
Jul 18, 2025
Results posted
Oct 2, 2026
Last update
Oct 2, 2026

Study contacts

Danielle Davis
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion